The predominant pathologicalfeature of tauopathies, including Alzheimer′s disease, is theintraneuronal deposition of the tau protein, hence the developmentof novel forms of treatments and prevention targeting tau proteinis considered a promising strategy.44 Towardthis direction, a possible approach is to test small compounds fortheir inhibitory activity against the aggregation of tau. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.